SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Therapies for rare diseases: therapeutic modalities, progress and challenges ahead
1 references·2 citing·9 second hop
Therapies for rare diseases: therapeutic modalities, progress and challenges ahead (2019)Therapies for rare diseases: therapeutic …Diagnosing the decline in pharmaceutical R&D efficiency (2012)Diagnosing the decline in pha…Using four decades of FDA orphan drug designations to describe trends in rare disease drug development: substantial growth seen in development of drugs for rare oncologic, neurologic, and pediatric-onset diseases (2021)Using four decades of FDA orp…Approval success rates of drug candidates based on target, action, modality, application, and their combinations (2021)Approval success rates of dru…Rise and fall of modern medicine (1999)Can the pharmaceutical industry reduce attrition rates? (2004)How to improve R&D productivity: the pharmaceutical industry's grand challenge (2010)Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework (2014)Are Ideas Getting Harder to Find? (2020)Generating Theory by Abduction (2021)Innovation in the pharmaceutical industry: New estimates of R&D costs (2016)Developing Drugs For Developing Countries (2006)Rare diseases and orphan drugs (2012)
this work references cited by second hop

References

  • 2012Diagnosing the decline in pharmaceutical R&D efficiency1,978 cited

Cited by

  • 2021Approval success rates of drug candidates based on target, action, modality, application, and their combinations113 cited
  • 2021Using four decades of FDA orphan drug designations to describe trends in rare disease drug development: substantial growth seen in development of drugs for rare oncologic, neurologic, and pediatric-onset diseases96 cited

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work